小分子靶向抗炎药物的研究进展

Research Progress of Small Molecule Targeted Anti-Inflammatory Drugs

摘要: 炎症是一种常见的病理过程，在各种疾病的发生发展过程中起重要作用。炎症的发生、发展及转归涉及多种分子机制，包括JAK信号通路和TLR信号通路活化等。临床常用的抗炎药物包括甾体抗炎药和非甾体抗炎药，都存在诸多药物不良反应，限制了其临床使用。近年来，研究者们开发了一系列小分子靶向抗炎化合物，包括JAK、TLR4、MyD88、NF-κB和PDE4抑制剂等，在类风湿性关节炎、炎症性肠病和特应性皮炎等炎症相关疾病中表现出良好的治疗效果。针对性合成选择性靶向药物具有良好的研究前景。本文综述了针对几个关键炎症信号通路的小分子靶向抗炎药物的研究进展，旨在为炎症性疾病的治疗提供更优的策略。

Abstract: Inflammation is a common pathological process that plays an important role in the development of various diseases. The occurrence, progression, and resolution of inflammation involve multiple molecular mechanisms, including the JAK and TLR signaling pathways, etc. At present, steroidal anti-inflammatory drugs and nonsteroidal anti-inflammatory drugs are commonly used in clinical. But both of which have many adverse drug reactions, their clinical uses are limited. In recent years, researchers have developed a series of small molecule targeted anti-inflammatory compounds that have good therapeutic effects in inflammation related diseases such as rheumatoid arthritis, inflammatory bowel disease, and atopic dermatitis. For example, JAK inhibitors, TLR4 inhibitors, MyD88 inhibitors, NF-κB inhibitors, and PDE4 inhibitors, etc. Targeted synthesis of selective targeted drugs has good research prospects. This article reviews the research progress of small molecule targeted anti-inflammatory drugs developed for several key inflammatory signaling pathways, aiming to provide better strategies for the treatment of inflammatory diseases.